Publisher Correction: UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.

Autor: Gozdecka M; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.; Wellcome Trust-MRC Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK., Meduri E; Wellcome Trust-MRC Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK., Mazan M; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.; Wellcome Trust-MRC Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK., Tzelepis K; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK., Dudek M; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK., Knights AJ; Genomics of Gene Regulation, Wellcome Trust Sanger Institute, Hinxton, UK., Pardo M; Proteomic Mass Spectrometry, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK., Yu L; Proteomic Mass Spectrometry, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK., Choudhary JS; Proteomic Mass Spectrometry, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK., Metzakopian E; Mouse Genomics, Wellcome Trust Sanger Institute, Hinxton, UK., Iyer V; Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK., Yun H; Wellcome Trust-MRC Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK., Park N; Sequencing Research Group, Wellcome Trust Sanger Institute, Cambridge, UK., Varela I; Instituto de Biomedicina y Biotecnología de Cantabria (CSIC-UC-Sodercan), Departamento de Biología Molecular, Universidad de Cantabria, Santander, Spain., Bautista R; New Pipeline Group, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK., Collord G; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK., Dovey O; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK., Garyfallos DA; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK., De Braekeleer E; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK., Kondo S; Laboratory of Molecular Genetics, Institute of Medical Science, University of Tokyo, Tokyo, Japan., Cooper J; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK., Göttgens B; Cambridge Institute for Medical Research and Wellcome Trust-Medical Research Council, Stem Cell Institute and Department of Haematology, University of Cambridge, Cambridge, UK., Bullinger L; Department of Internal Medicine III, Ulm University Medical Centre, Ulm, Germany.; Medical Department, Division of Hematology, Oncology and Tumour Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany., Northcott PA; Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, TN, USA., Adams D; Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK., Vassiliou GS; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK. gsv20@sanger.ac.uk.; Wellcome Trust-MRC Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK. gsv20@sanger.ac.uk.; Department of Haematology, Cambridge University Hospitals NHS Trust, Cambridge, UK. gsv20@sanger.ac.uk., Huntly BJP; Wellcome Trust-MRC Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK. bjph2@cam.ac.uk.; Cambridge Institute for Medical Research and Wellcome Trust-Medical Research Council, Stem Cell Institute and Department of Haematology, University of Cambridge, Cambridge, UK. bjph2@cam.ac.uk.; Department of Haematology, Cambridge University Hospitals NHS Trust, Cambridge, UK. bjph2@cam.ac.uk.

Publikováno v: Nature genetics [Nat Genet] 2022 Jul; Vol. 54 (7), pp. 1062.

METTL1-mediated m ⁷ G modification of Arg-TCT tRNA drives oncogenic transformation.

Autor: Orellana EA; Stem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Liu Q; Stem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Yankova E; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK; Milner Therapeutics Institute, University of Cambridge, Puddicombe Way, Cambridge CB2 0AW, UK; Storm Therapeutics Ltd., Moneta Building (B280), Babraham Research Campus, Cambridge CB22 3AT, UK., Pirouz M; Stem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., De Braekeleer E; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK., Zhang W; Department of Pathology, Cancer Center, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA., Lim J; Department of Pathology, Cancer Center, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA., Aspris D; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK; Karaiskakio Foundation, Nicandrou Papamina Avenue, 2032 Nicosia, Cyprus., Sendinc E; Division of Newborn Medicine and Epigenetics Program, Department of Medicine, Boston Children's Hospital, Boston, MA 02115, USA., Garyfallos DA; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), University of Cambridge, Puddicombe Way, Cambridge CB2 0AW, UK., Gu M; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK., Ali R; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA., Gutierrez A; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA., Mikutis S; Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK., Bernardes GJL; Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK., Fischer ES; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA., Bradley A; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), University of Cambridge, Puddicombe Way, Cambridge CB2 0AW, UK., Vassiliou GS; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK; Karaiskakio Foundation, Nicandrou Papamina Avenue, 2032 Nicosia, Cyprus; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Puddicombe Way, Cambridge CB2 0AW, UK., Slack FJ; Department of Pathology, Cancer Center, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Harvard Initiative for RNA Medicine, Boston, MA 02115, USA., Tzelepis K; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK; Milner Therapeutics Institute, University of Cambridge, Puddicombe Way, Cambridge CB2 0AW, UK; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Puddicombe Way, Cambridge CB2 0AW, UK. Electronic address: kt404@cam.ac.uk., Gregory RI; Stem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Harvard Initiative for RNA Medicine, Boston, MA 02115, USA. Electronic address: rgregory@enders.tch.harvard.edu.

Publikováno v: Molecular cell [Mol Cell] 2021 Aug 19; Vol. 81 (16), pp. 3323-3338.e14. Date of Electronic Publication: 2021 Aug 04.

Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia.

Autor: Yankova E; Milner Therapeutics Institute, University of Cambridge, Cambridge, UK.; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK.; Storm Therapeutics Ltd, Cambridge, UK., Blackaby W; Storm Therapeutics Ltd, Cambridge, UK., Albertella M; Storm Therapeutics Ltd, Cambridge, UK., Rak J; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK.; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK., De Braekeleer E; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK.; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK., Tsagkogeorga G; Milner Therapeutics Institute, University of Cambridge, Cambridge, UK.; Storm Therapeutics Ltd, Cambridge, UK., Pilka ES; Evotec (UK) Ltd, Abingdon, UK., Aspris D; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK.; The Center for the Study of Hematological Malignancies/Karaiskakio Foundation, Nicosia, Cyprus., Leggate D; Storm Therapeutics Ltd, Cambridge, UK., Hendrick AG; Storm Therapeutics Ltd, Cambridge, UK., Webster NA; Storm Therapeutics Ltd, Cambridge, UK., Andrews B; Storm Therapeutics Ltd, Cambridge, UK., Fosbeary R; Storm Therapeutics Ltd, Cambridge, UK., Guest P; Storm Therapeutics Ltd, Cambridge, UK., Irigoyen N; Division of Virology, Department of Pathology, University of Cambridge, Cambridge, UK., Eleftheriou M; Milner Therapeutics Institute, University of Cambridge, Cambridge, UK., Gozdecka M; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK., Dias JML; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK., Bannister AJ; The Gurdon Institute and Department of Pathology, University of Cambridge, Cambridge, UK., Vick B; Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany.; German Consortium for Translational Cancer Research (DKTK), Munich, Germany., Jeremias I; Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany.; German Consortium for Translational Cancer Research (DKTK), Munich, Germany.; Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig Maximilians University München, Munich, Germany., Vassiliou GS; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK.; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.; The Center for the Study of Hematological Malignancies/Karaiskakio Foundation, Nicosia, Cyprus., Rausch O; Storm Therapeutics Ltd, Cambridge, UK. oliver.rausch@stormtherapeutics.com., Tzelepis K; Milner Therapeutics Institute, University of Cambridge, Cambridge, UK. kt404@cam.ac.uk.; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK. kt404@cam.ac.uk.; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK. kt404@cam.ac.uk.; The Gurdon Institute and Department of Pathology, University of Cambridge, Cambridge, UK. kt404@cam.ac.uk., Kouzarides T; Milner Therapeutics Institute, University of Cambridge, Cambridge, UK. t.kouzarides@gurdon.cam.ac.uk.; The Gurdon Institute and Department of Pathology, University of Cambridge, Cambridge, UK. t.kouzarides@gurdon.cam.ac.uk.

Publikováno v: Nature [Nature] 2021 May; Vol. 593 (7860), pp. 597-601. Date of Electronic Publication: 2021 Apr 26.

RAD52 and ERCC6L/PICH have a compensatory relationship for genome stability in mitosis.

Autor: Osia, Beth¹ (AUTHOR), Merkell, Arianna¹ (AUTHOR), Lopezcolorado, Felicia Wednesday¹ (AUTHOR), Ping, Xiaoli¹ (AUTHOR), Stark, Jeremy M.¹ (AUTHOR) jstark@coh.org

Publikováno v: PLoS Genetics. 11/19/2024, Vol. 20 Issue 11, p1-36. 36p.

Decoding the epitranscriptome: a new frontier for cancer therapy and drug resistance.

Autor: Tang, Lu^1,2 (AUTHOR), Tian, Hua^1,3 (AUTHOR), Min, Qi⁴ (AUTHOR), You, Huili^1,5 (AUTHOR), Yin, Mengshuang^1,5 (AUTHOR), Yang, Liqiong^1,5 (AUTHOR), Zhao, Yueshui^1,5 (AUTHOR), Wu, Xu^1,5 (AUTHOR), Li, Mingxing^1,5 (AUTHOR), Du, Fukuan^1,5 (AUTHOR), Chen, Yu^1,5 (AUTHOR), Deng, Shuai^1,5 (AUTHOR), Li, Xiaobing^1,5 (AUTHOR), Chen, Meijuan^1,5 (AUTHOR), Gu, Li¹ (AUTHOR), Sun, Yuhong¹ (AUTHOR), Xiao, Zhangang^1,5 (AUTHOR) zhangangxiao@swmu.edu.cn, Li, Wanping^1,5 (AUTHOR) 675832860@qq.com, Shen, Jing^1,5 (AUTHOR) jingshen@swmu.edu.cn

Publikováno v: Cell Communication & Signaling. 10/21/2024, Vol. 22 Issue 1, p1-35. 35p.